Sygnis Pharma AG has completed patient recruitment for its AXIS 2 Study, a randomized, double-blind study designed to demonstrate the efficacy of AX200 (G-CSF) for the treatment of patients with acute ischemic stroke.
“With the completion of patient enrolment we have reached the next milestone of the clinical development of AX200 for the treatment of acute stroke. After the completion of a 3 month monitoring period of this last patient, we will enter the crucial evaluation phase during which we will analyse all collected data and, as a result, gain clarity on the potential of AX200 for the treatment of acute stroke,” says Frank Rathgeb, MD, chief medical officer of Sygnis.
Based on these findings, Sygnis will evaluate the options for the further development or commercialization of AX200. The company may start an additional clinical study to confirm the efficacy of AX200 for the treatment of acute stroke by itself or with an appropriate pharma partner, or it may out-license the AX200 project.
Release Date: August 9, 2011
Source: Sygnis Pharma AG
Filed Under: Drug Discovery